Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Eva Walde strengthens Senzime’s Board of Directors

Press release: Uppsala, October 19, 2020. Senzime announces that Eva Walde is appointed new acting Board Member to be elected at the next shareholder’s meeting.   Eva has a Master's degree in economics from the Gothenburg School of Economics and over 20 years of experience in leading roles in companies such as Johnson & Johnson, Pfizer and Thermo Fisher. Eva is currently a Board member of Sedana Medical AB (publ.), a volatile anaesthetic delivery company, and the VP of Marketing at Olink AB."We are very pleased to appoint such an experienced person as Eva Walde to Senzime's Board.

Dicot AB receive approximately 7.6 MSEK through the warrants of series TO1 2019

Press release: Uppsala, October 19, 2020. Dicot AB (”Dicot” or the ”Company”) announce the outcome regarding exercising of warrants of series TO1 2019 for the subscription of new shares. In total, 2,894,950 warrants were exercised, corresponding to approximately 37.2 percent of the total number of warrants of series TO1 2019 issued, for the subscription of 5,326,701 shares at a price of SEK 1.42 per shares. Through the subscription of shares using warrants Dicot will receive approximately 7.6 MSEK, before issuing costs.Background During the third quarter of 2019 Dicot carried out a right’

Amsterdam UMC chooses Sectra for enterprise-wide radiology imaging

Linköping, Sweden – October 19, 2020 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) has signed a seven-year contract with one of the largest healthcare providers in the Netherlands — Amsterdam UMC. Sectra will install its imaging solution throughout the radiology and nuclear medicine departments to boost reading and reporting efficiency and enhance collaboration across its two hospitals.Amsterdam UMC is the result of a merger in 2018 of the Academic Medical Center (AMC) and the VU University Medical Center (VUmc). With Sectra’s

Reminder: C-RAD Web Presentation Interim Report Q3 2020

Invitation to join the presentation of the C-RAD Q3 interim report Date: Thursday October 22, 2020 / kl. 11:00 CET Venue: Online Presentation Topic: C-RAD Interim Report Q3 2020 Procedure: Please register online through the website:   https://attendee.gotowebinar.com/register/7890477381628997900 After the registration, you will receive a confirmation via email. A recording of the presentation will be made accessible on the C-RAD website after the presentation. About C-RAD C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly

NOTE’s Interim Report January–September 2020

Financial performance July–September• Sales amounted to SEK 433 (434) million.• Operating profit was up by 14% to SEK 36 (32) million.• Operating margin widened by 1.0 percentage points to 8.3% (7.3%).• Profit after net financial items increased by 15% to SEK 33 (30) million.• Profit after tax increased by 27% to SEK 28 (22) million, corresponding to SEK 0.98 (0.81) per     share.• Cash flow after investments of SEK 1 (1) million, or SEK 0.04 (0.04) per share. Financial performance January–September • Sales increased by 10% to SEK 1,408 (1,277) million.• Operating

Oncopeptides has submitted an Investigational New Drug application to FDA for the second drug candidate from the PDC platform

STOCKHOLM — October 19, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), for OPD5 - a second drug candidate based on the proprietary Peptide Drug Conjugate platform (PDC).Oncopeptides plans to initiate clinical development of OPD5 with an open-label phase 1, dose escalation study on safety and tolerability of OPD5 as a myeloablative regimen followed by Autologous Stem Cell Transplantation in patients with relapsed refractory multiple myeloma. The

SpectrumOne gets trademark protection in the EU

SpectrumOne has been granted trademark protection in the EU from European Union Intellectual Property Office and thus no longer has any obstacles to investing, expanding and partnering with partners within the EU.  The company has previously communicated its plans to expand in Europe with the help of partners, and brand protection has been a factor to take into account in negotiations and discussions. Brand protection provides strong protection in the market that is to become our primary market, de facto the world's strongest economy. Hosni Teque-Omeirat, CEO of SpectrumOne says “It

Azelio business update - Azelio has successfully verified its energy storage system’s performance

Azelio has successfully generated verification data so that the performance of the company’s energy storage system has been verified in accordance with the specification of 13 kW output power with a storage capacity corresponding to 13 hours of electricity production. The company has thus reached an important milestone in the commercialization of its energy storage system. The certification body DNV-GL has announced that it will issue an initial verification report within four weeks, which will be made available to Azelio’s customers. The verification project has thus resulted in an

Welcome to Investor’s Capital Markets Day 2020

Investor will host a virtual Capital Markets Day to provide an update on Investor’s strategic priorities and engaged ownership model. In addition, the CEOs of the Patricia Industries companies will present their companies and their focus going forward. The Capital Markets Day, which takes place on November 13, 2020, starts at 12:30 CET and is expected to conclude at approximately 3:30pm CET. More details on the agenda and how to register will follow closer to the event. Welcome!

Interim Management Statement January-September 2020

“I am impressed by the management teams in our companies and the way they have handled a challenging year. They have stayed close to their customers, while quickly adapting their operations. I also believe that our companies have done an excellent job in balancing necessary cost reductions with continuation of prioritized investments to future-proof the businesses and emerge as long-term winners.”Johan Forssell, President & CEO of Investor  Highlights during the third quarter•    Adjusted net asset value (NAV) amounted to SEK 537,358m (SEK 702 per share) on September 30, 2020, an

Invitation 13.11: Press Conference on health effects of irregular working hours and shift work – how to avoid the risks? New research results and recommendations available. (Live stream)

Invitation for media Welcome to the Press Conference on 13 November How do shift work and irregular working hours affect the workers’ health and work participation? How to avoid the risks? New research results and recommendations are published.Time:   Friday 13 November 2020 at  9–10.15 am (CET, Stockholm, Copenhagen and Oslo), 10 - 11 am (Helsinki time)The Press Conference will be streamed online https://ttl.livestriimi.fi/wowsymposium/ The characteristics of working hours are changing rapidly and becoming increasingly flexible. In addition, every fifth employee, mostly in

Saab’s Results January-September 2020

Saab presents the results for January-September 2020 earlier than previously announced.Statement by the President and CEO Micael Johansson: The corona pandemic has continued to impact the world negatively and not least the global aviation industry. For Saab, the uncertainty surrounding Covid-19 has mainly been associated with supply chain disruptions within the company’s business areas and the market conditions for the civil business. Due to the ongoing pandemic and drawn-out global recovery, Saab now sees an increased risk related to the effects of Covid-19. In recent assessments,

KGI Asia selects Itiviti’s multi-asset OMS solution to trade global markets

Hong Kong, October 19, 2020 – Itiviti, a leading technology, and service provider of electronic trading and connectivity solutions to financial institutions worldwide, today announced that KGI Asia (Hong Kong), one of the largest equity brokers in Hong Kong has selected Itiviti’s multi-asset order management solution for high and low-touch trading.Using Itiviti’s multi-asset order management system, KGI Asia will be able to efficiently support its growing institutional, wealth management, and brokerage businesses. The new trading stack automates the firm’s entire trading operations across

Creating perfect edges in 2D-materials

Ultrathin materials such as graphene promise a revolution in nanoscience and technology. Researchers at Chalmers University of Technology, Sweden, have now made an important advance within the field. In a recent paper in Nature Communications  they present a method for controlling the edges of two-dimensional materials using a ‘magic’ chemical.“Our method makes it possible to control the edges – atom by atom – in a way that is both easy and scalable, using only mild heating together with abundant, environmentally friendly chemicals,

Wallenstam launches four climate targets

As a part of Wallenstam’s sustainability work, four climate targets are now being introduced.  The aim of the targets is to further reduce the carbon footprint from the building operations and from the properties’ energy consumption and residual waste. In addition, all business trips shall be carried out in a carbon-neutral way.“In Sweden, we are living as if there are resources equivalent to four planet Earths. Wallenstam wants to and can make a difference. We have a deliberate long-term sustainability strategy, work with prioritized goals according to Agenda 2030 and we are now sharpening

Handelsbanken’s interim report for January – September 2020 will be presented on Wednesday, 21 October

Handelsbanken publishes its interim report for January ­– September 2020 at 7:00 a.m. CET on Wednesday, 21 October. The Group Chief Executive Carina Åkerström will present the Bank’s interim report at 9:00 a.m. CET. at a meeting with the media, at Handelsbanken’s head office, Grevgränd 3, Stockholm. The presentation will be held in Swedish, with simultaneous interpretation into English. A link to the presentation will be available at handelsbanken.com/ir. Please note that the number of places is limited, in accordance with the recommendations of the Public Health Agency of Sweden.

ZICCUM to publish White Paper on world’s first industrial air-drying of vaccines using its LaminarPace technology

The White Paper will describe in detail the integration of Ziccum AB’s LaminarPace technology into a Fill and Finish (F/F) manufacturing facility of the world’s first plant for formulating and packaging thermostable air-dried vaccines at volume. The new vaccines could be produced at an estimated -65% lower OPEX and -50% lower CAPEX cost than today’s freeze drying (lyophilization) F/F plants. The vaccines produced could be stored and transported at ambient temperatures, requiring no Cold Chain.The vast majority of today’s F/F plants – the final stage in vaccine manufacture and distribution -

Calliditas Announces Poster and Presentation at ASN Digital Kidney Week 2020

Calliditas Therapeutics AB (publ) (”Calliditas”) today announced upcoming presentations concerning Nefecon, its lead product candidate, at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined conference, to be held virtually October 19–25, 2020.At the "Glomerular Diseases: Clinical, Outcomes, and Trials” session, a poster will be presented by Professor Jonathan Barratt from the Mayer IgA Nephropathy Laboratory at the University of Leicester. The poster describes the design of the NefIgArd trial, which is exploring the effect of Nefecon in patients with IgA Nephropathy (IgAN)

Trixeo Aerosphere receives positive CHMP opinion

19 October 2020 07:00 BST Trixeo Aerosphere recommended for approval in the EUby CHMP for the maintenance treatment of COPD Recommendation of triple-combination therapy based onpositive results from ETHOS and KRONOS Phase III trials AstraZeneca's Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) has been recommended for marketing authorisation in the European Union (EU) for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled

Forxiga HF receives positive CHMP opinion

19 October 2020 07:00 BST Forxiga recommended for approval in the EU by CHMP for heart failure If approved, Forxiga would become the first SGLT2 inhibitor indicated for heart failure with reduced ejection fraction in patients with and without type-2 diabetes AstraZeneca's Forxiga (dapagliflozin) has been recommended for an indication extension of its marketing authorisation in the European Union (EU) for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and without type-2 diabetes (T2D). Heart failure (HF) is a life-threatening

Press Release: Everfuel contemplates private placement and listing on Merkur Market

Everfuel A/S (Everfuel), a minority-owned company of Nel ASA (Nel) is contemplating a private placement and admission to trading on Merkur Market, which is part of the Oslo Stock Exchange. "We’re happy to see the positive development Everfuel has made over the last year and a half, and with the plans the company has for further expansions in the near future, we see this development as very positive," says Jon André Løkke, CEO of Nel. Nel holds a 19.9% ownership in Everfuel, and has pre-committed to subscribe shares in the private placement, equal to around EUR 0.8 million. Link to

Everfuel A/S: Contemplated private placement and admission to trading of leading European green hydrogen fuel company on Merkur Market

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Herning, 19 October 2020 – Everfuel A/S (“Everfuel” or the “Company”) has engaged SpareBank 1 Markets AS (the “Manager”) to advise on and carry out a private placement of up to 13,200,000 million new shares in the Company (the “Private Placement”) raising gross

Selvaag Bolig ASA: Management changes at Selvaag Bolig

Rolf Thorsen is stepping down as CEO of Selvaag Bolig ASA. He is being replaced by Sverre Molvik as CEO and Øystein Klungland as COO.   Following an evaluation process, Thorsen and the board have come to the conclusion that he will step down with immediate effect after leading the company since May 2019. “Thorsen’s time with the company has proved shorter than we had planned,” says chair Olav H Selvaag. “Nevertheless, I’d like to thank him for our collaboration during the time we’ve worked together.” Molvik is taking over as CEO immediately. He has been with the company for 10

Targovax announces accepted abstract at SITC

Oslo, Norway, 19 October 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that an abstract on the mesothelioma trial has been accepted and will be presented at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting, 9 -14 November 2020.The abstract presents the 12-month analysis of biomarkers and clinical outcome from the phase I/II trial in malignant pleural mesothelioma where ONCOS-102 is added to standard of care chemotherapy (pemetrexed / cisplatin). This

There are no items matching the current filter
There are no more items matching the current filter
Back to top